Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

TC BioPharm is set to begin preclinical studies for its lead therapy, TCB 008, aimed at treating monkeypox. This development could potentially position the company as a key player in addressing the monkeypox outbreak.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:40 pm

TC BioPharm is set to begin preclinical studies for its lead therapy TCB008 aimed at treating monkeypox. The company plans to collaborate with an infectious disease center to expedite these studies.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 8:02 pm

Recursion Pharmaceuticals shares fell 11.6% after announcing Phase 2 data for a treatment for Cerebral Cavernous Malformation. Nikola shares also dipped 10.4%. Meanwhile, Sify Technologies surged 103% after achieving a significant certification, and SPAR Group rose 65% following an acquisition agreement.

Portfolio Pulse from Avi Kapoor

September 03, 2024 | 5:41 pm

TC BioPharm shares rose as the company announced dosing 5 new patients in its ACHIEVE Phase 2b trial.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 2:08 pm

TC Biopharm (TCBP) has dosed five new patients in its ACHIEVE Phase 2b trial, which is a significant step in their clinical development process.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:41 pm

Affirm Holdings, Inc. (AFRM) shares surged 18% in pre-market trading due to better-than-expected Q4 earnings and positive Q1 guidance. Other notable pre-market movers include BioCardia, Inc. (BCDA) with a 109.5% gain after FDA clearance, and Big Lots, Inc. (BIG) with a 30.5% decline amid bankruptcy concerns.

Portfolio Pulse from Avi Kapoor

August 29, 2024 | 9:37 am

TC BioPharm's shares rose following the grant of a European patent for using modified gamma delta cells in cancer and viral treatments.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 6:38 pm

TC BioPharm has been granted a European patent for the use of modified gamma delta cells in treating cancer and viral indications. This development could enhance their therapeutic offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:51 pm

TC BioPharm shares are trading higher after the company announced it regained compliance with the Nasdaq listing rule 5550(b).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 7:54 pm

TC BioPharm has regained compliance with Nasdaq Listing Rule 5550(b), ensuring its continued listing on the Nasdaq exchange.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.